Medeon Biodesign (6499) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 益安

Medeon Biodesign (6499) reported revenue of NT$38 million for Oct 2026, +2.7% year on year and -83.6% from the previous month. Revenue for Jan–Oct 2026 was NT$570.9 million (+67.2% year on year).

Year-on-year revenue growth: 4 months in a row. →

In Oct 2026, it ranked No. 109 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$28.5 million24/10Nov 2024 NT$24.6 millionDec 2024 NT$24.2 millionJan 2025 NT$27 millionFeb 2025 NT$36.2 million25/02Mar 2025 NT$38.7 millionApr 2025 NT$35.9 millionMay 2025 NT$35.2 millionJun 2025 NT$39.2 million25/06Jul 2025 NT$25.1 millionAug 2025 NT$29.4 millionSep 2025 NT$37.8 millionOct 2025 NT$37 million25/10Nov 2025 NT$41.7 millionDec 2025 NT$36.2 millionJan 2026 NT$30.3 millionFeb 2026 NT$47.9 million26/02Mar 2026 NT$36.1 millionApr 2026 NT$37.1 millionMay 2026 NT$33 millionJun 2026 NT$36.5 million26/06Jul 2026 NT$42.4 millionAug 2026 NT$38.1 millionSep 2026 NT$231.5 millionOct 2026 NT$38 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$38 million+2.7%-83.6%
Sep 2026NT$231.5 million+513.1%+508.1%
Aug 2026NT$38.1 million+29.5%-10.3%
Jul 2026NT$42.4 million+68.8%+16.3%
Jun 2026NT$36.5 million-7.1%+10.5%
May 2026NT$33 million-6.3%-11.1%
Apr 2026NT$37.1 million+3.4%+2.8%
Mar 2026NT$36.1 million-6.7%-24.6%
Feb 2026NT$47.9 million+32.3%+58.3%
Jan 2026NT$30.3 million+12.3%-16.5%
Dec 2025NT$36.2 million+49.6%-13.0%
Nov 2025NT$41.7 million+69.1%+12.7%
Oct 2025NT$37 million+29.8%-2.1%
Sep 2025NT$37.8 million+58.4%+28.5%
Aug 2025NT$29.4 million-53.6%+16.9%
Jul 2025NT$25.1 million+42.5%-35.9%
Jun 2025NT$39.2 million+77.6%+11.4%
May 2025NT$35.2 million+70.2%-1.9%
Apr 2025NT$35.9 million+73.2%-7.2%
Mar 2025NT$38.7 million+107.1%+6.9%
Feb 2025NT$36.2 million+153.7%+34.3%
Jan 2025NT$27 million+90.2%+11.3%
Dec 2024NT$24.2 million+10.9%-1.7%
Nov 2024NT$24.6 million+60.4%-13.5%
Oct 2024NT$28.5 million+56.0%+19.5%

Jan–Oct 2026 cumulative: NT$570.9 million (+67.2% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Medeon Biodesign vs PEC / Medeon Biodesign vs Lotus Pharm / Medeon Biodesign vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

累計營收較去年增長,係認列Cross-Seal資產讓與合約相關和解金、及CDMO事業體業務成長所致

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16